Randomized, double-blind, placebo-controlled, phase 3 study

Ended Project Grant Awarded Last action

Award ID
R01AG065253
Recipient
Awarding agency
Obligated
$126,190,244

Award facts

Assistance listing
93.866 Aging Research
Completion date
Funding
  • $113,690,244.00 Federal
  • $12,500,000.00 Non-federal
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $2,265,244 $0
Amendment $425,000 $0
Amendment $6,500,000 $0
Amendment $6,500,000 $0
Amendment $3,500,000 $0
Amendment $3,500,000 $0
Amendment $3,500,000 $0
Amendment $3,500,000 $0
Amendment $11,000,000 $0
Amendment $11,000,000 $0
Amendment $11,000,000 $0
Amendment Randomized, double-blind, placebo-controlled, phase 3 study - covid supplement $11,000,000 $0
Amendment $0 $0
Amendment $0 $0
Amendment $12,500,000 $0
Amendment $12,500,000 $12,500,000
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Original award $15,000,000 $0
Show all 22

Quick answers

Who received award R01AG065253?

R01AG065253 was awarded to Alzheon, Inc. by National Institute on Aging (National Institutes of Health) on August 15, 2020.

How much is award R01AG065253 worth?

$126,190,244 has been obligated on R01AG065253: $113,690,244 in federal funding and $12,500,000 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award